Lung NeoplasmsNCT06259461
Machine Learning to Construct an Association Model for Lung Cancer and Environmental Hormone
An observational study of Lung Neoplasms, run by Pei-Hung Liao at 2 sites in Taiwan.
Trial summary
To apply machine learning to construct an association model regarding lung cancer and environmental hormones to more comprehensively identify factors that may lead to lung cancer and to improve existing lung cancer nursing assessments. Read more about this study
- Who is it for?
- Ages 20 years and olderHealthy volunteers can take part
- Conditions the study is for
- Lung Neoplasms
- How many people
- 128 participants
- Where
- 2 sitesTaiwan
- Study dates
- 1 Jan 2023to 30 Jun 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study focused on lung cancer cases and investigated the association with exposure to environmental hormones
Who may be able to join
- 20 years or older;
- conscious, without mental disorders;
- able to use Mandarin to communicate, had a smartphone or tablet computer and could operate it by themselves,
- and were willing to participate in the study after the reasons for participation were explained and a consent form was signed, indicating their consent.
Who cannot join
- The exclusion criteria were those who could not understand the content of the nursing assessment questions and those with mental disorders.
Trial locations and contacts
2 sites in 1 country.
Taiwan2 sites
National Taipei university of nursing and health science
Taipei
National Taiwan University, Cancer Center
Taipei
About this study
Official title: Identifying the Risk of Lung Cancer Linked to Environmental Hormones
To apply machine learning to construct an association model regarding lung cancer and environmental hormones to more comprehensively identify factors that may lead to lung cancer and to improve existing lung cancer nursing assessments.
Read the detailed description
The present study is exploratory, and its design was divided into three stages: Stage 1 explored the environmental hormonal risk factors for lung cancer and constructed an association model using machine learning algorithms. Stage 2 validated the results of the association model with better predictive results in clinical settings. Stage 3 involved recommendations for reconstructing nursing assessments based on the results of the clinical model validation. The three stages are summarized as follows.
- Conditions
- Lung Neoplasms
- Keywords
- Environmental Substance
- Medical subject headings
- Lung Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
identify factors that may lead to lung cancer and environmental hormones.
This association model can assist in identifying the risk groups of lung cancer and advising physicians on the appropriate environmental hormone testing and treatment to provide nursing guidance and medical advice
Measured: the database research samples from May 2014 to December 2020.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Feb 2024
- Study start1 Jan 2023
- Primary completion30 Jun 2024 (estimated)
- Study completion30 Jun 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 128 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Pei-Hung Liao
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Pei-Hung Liao, National Taipei University of Nursing and Health Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06259461
- Sponsor's protocol ID
- 202204055RINA
- Status last verified
- Feb 2024
- First submitted
- 20 Jan 2024
- Last updated
- 14 Feb 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Identifying the Risk of Lung Cancer Linked to Environmental Hormones
- ClinicalTrials.gov ID
- NCT06259461
- Acronym / sponsor ID
- 202204055RINA
- Conditions
- Lung Neoplasms
- Keywords
- Environmental Substance
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 128 participants (estimated)
- Lead sponsor
- Pei-Hung LiaoUniversity, hospital or other
- Study start
- 1 Jan 2023 (actual)
- Primary completion
- 30 Jun 2024 (estimated)
- Study completion
- 30 Jun 2024 (estimated)
- First posted
- 14 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To apply machine learning to construct an association model regarding lung cancer and environmental hormones to more comprehensively identify factors that may lead to lung cancer and to improve existing lung cancer nursing assessments.
Detailed description
The present study is exploratory, and its design was divided into three stages: Stage 1 explored the environmental hormonal risk factors for lung cancer and constructed an association model using machine learning algorithms. Stage 2 validated the results of the association model with better predictive results in clinical settings. Stage 3 involved recommendations for reconstructing nursing assessments based on the results of the clinical model validation. The three stages are summarized as follows.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study focused on lung cancer cases and investigated the association with exposure to environmental hormones
Key inclusion criteria (4 listed)
- 20 years or older;
- conscious, without mental disorders;
- able to use Mandarin to communicate, had a smartphone or tablet computer and could operate it by themselves,
- and were willing to participate in the study after the reasons for participation were explained and a consent form was signed, indicating their consent.
Key exclusion criteria (1 listed)
- The exclusion criteria were those who could not understand the content of the nursing assessment questions and those with mental disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
identify factors that may lead to lung cancer and environmental hormones.
Time frame: the database research samples from May 2014 to December 2020.
This association model can assist in identifying the risk groups of lung cancer and advising physicians on the appropriate environmental hormone testing and treatment to provide nursing guidance and medical advice
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Feb 2024.
- Individual participant dataSharing planned: No
Related trials for Lung Neoplasms
RecruitingPhase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Carcinoma, Non-small-Cell Lung
RecruitingPhase 1/2
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ovarian Cancer, Non-small Cell Lung Cancer
Active, not recruiting
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
Bone Metastases, HER2-positive Breast Cancer
Not yet recruitingObservational study
The Impact of Rheumatoid Arthritis Treatments on the Modulation of Extracellular Vesicles and Other Biomarkers Involved in the Development of Lung Cancer
Rheumatoid Arthritis (RA), Lung Neoplasms
Active, not recruitingPhase 3
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Advanced or Metastatic Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Neoplasms, run by Pei-Hung Liao at 2 sites in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
identify factors that may lead to lung cancer and environmental hormones. (time frame: the database research samples from May 2014 to December 2020.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2024.